Overcoming Difficulties In GPCR Antibody Discovery Using Biocytogen’s Renmice-Based Platform
Speaker: Yanan Guo, Ph.D.
Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals
GPCRs (G protein-coupled receptor) are the most abundant membrane protein in the human genome, and are targeted by approximately one-third of drugs on the market. However, the difficulty in antigen preparation and novel GPCR-targeting antibody screening has posed significant challenges in the field of GPCR antibody discovery. In this webinar, Dr. Yanan Guo outlined how our target knock-out RenMice and established GPCR antibody discovery platform can enable efficient GPCR antibody discovery and development, with a focus on our leading CCR8 program.
